Risk-adapted nodal evaluation in stage IA non-small cell lung cancer: a population-based competing-risk analysis

Area of Science:

• Oncology
• Thoracic Surgery
• Cancer Staging

Background:

• The benefit of extensive lymph node evaluation in stage IA non-small cell lung cancer (NSCLC) is debated amidst surgical de-escalation.
• Assessing lymph node status is crucial for accurate staging and treatment planning in NSCLC.

Purpose of the Study:

• To investigate the association between the number of examined lymph nodes and survival outcomes in surgically treated stage IA NSCLC patients.
• To determine if intensified nodal evaluation impacts cancer-specific mortality in early-stage NSCLC.

Main Methods:

• A population-based cohort study using the Surveillance, Epidemiology, and End Results (SEER) database.
• Inclusion of patients with surgically treated pathologic stage IA (T1N0M0) NSCLC.
• Propensity score matching and Fine-Gray competing-risk models to analyze cancer-specific mortality based on the number of examined lymph nodes.

Main Results:

• Intensified nodal evaluation (≥6 examined lymph nodes) was associated with significantly lower cancer-specific mortality (5-year cumulative incidence 12.9% vs. 15.3%).
• Examined lymph nodes ≥6 remained independently associated with reduced cancer-specific mortality (SHR 0.78).
• The survival benefit was more pronounced in tumors >1 cm compared to tumors ≤1 cm.

Conclusions:

• Intensified lymph node evaluation shows a survival benefit in stage IA NSCLC, particularly for tumors larger than 1 cm.
• Findings support exploring a tumor size-based, risk-adapted strategy for surgical staging in early NSCLC.
• Balancing oncologic adequacy with surgical burden is key in managing early-stage NSCLC.